|
|
|
|
Vatalanib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving vatalanib together with pemetrexed disodium may kill more tumor cells. http://clinicaltrials.gov/ct2/show/NCT00390000Study of Cancer Drugs Vatalanib (also called PTK/ZK) and Pemetrexed Disodium (also called ALIMTA) for People with Advanced Cancer. http://clinicaltrials.mayo.edu/clinicaltrialdetails.cfm?trial_id=100608&title=Study%20of%20Cancer%20Drugs%20Vatalanib%20(also%20called%20PTK/ZK)%20and%20Pemetrexed%20Disodium%20(also%20called%20ALIMTA)%20for%20People%20with%20Advanced%20Cancer.Vatalanib (PTK787 / ZK222584) Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic ... is an abstact about early trial results from the ASCO 2006 meeting, and you can also ... http://www.gistsupport.org/treatments/emerging-treatments/inhibitors-of-kit-pdgfr-or-vegf/vatalanib-ptk787.phpVatalanib also increased interleukin-6 and vascular endothelial growth factor secretion in cultures of multiple myeloma cells adherent to bone marrow stem cells. http://training.dialog.com/onlinecourses/drug_pipeline/lesson4/file107.htmlPatients also receive vatalanib twice daily for 6 weeks at the MTD determined in phase I. Four weeks after the completion of chemoradiotherapy, patients proceed to adjuvant therapy http://www.cancer.gov/clinicaltrials/EORTC-26041 |
|
|